MOUNTAIN VIEW, Calif., Sept. 4 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. today announced that the Company will present at the Morgan Stanley Global Healthcare Unplugged Conference on Tuesday, September 9, 2008, at 10:20 am (ET) in New York City.
A live webcast of the presentation will be available on the Investor Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com/. A replay will also be available within 24 hours for seven days following the presentation.
About MAP Pharmaceuticals, Inc.
MAP Pharmaceuticals develops and plans to commercialize new therapies for children and adults who suffer from chronic conditions that it believes are not adequately treated by currently available medicines. The Company applies its proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. MAP Pharmaceuticals has two drug candidates, Unit Dose Budesonide and MAP0004, in late stage development for the potential treatment of pediatric asthma and migraine respectively. MAP Pharmaceuticals' pipeline also includes a drug candidate in early clinical development for the treatment of asthma and chronic obstructive pulmonary disease.
Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com/.
